Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone

被引:121
作者
Aumeeruddy, M. Zakariyyah [1 ]
Mahomoodally, M. Fawzi [1 ]
机构
[1] Univ Mauritius, Fac Sci, Dept Hlth Sci, Reduit, Mauritius
关键词
breast cancer; combination therapy; phytochemicals; piperine; sulforaphane; thymoquinone; ANTICANCER ACTIVITY; INDUCED APOPTOSIS; IN-VITRO; CELLS; EXPRESSION; EFFICACY; GROWTH; INHIBITION; ARREST; TRAIL;
D O I
10.1002/cncr.32022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite the significant advances in screening methods for early diagnosis, breast cancer remains a global threat and continues to be the leading cancer diagnosed in women, requiring effective therapy. Currently, combination therapy has become the hallmark of breast cancer treatment due to the high incidence of tumor recurrence and disease progression after monotherapeutic treatments, including surgery, radiotherapy, endocrine therapy, and chemotherapy. Over the past decades, there has been considerable interest in studying the anticancer effect of bioactive phytochemicals from medicinal plants combined with these conventional therapies. The rationale for this type of therapy is to use combinations of drugs that work by different mechanisms, thereby decreasing the likelihood that cancer cells will develop resistance, and also reduce the therapeutic dose and toxicity of single treatments. Three agents have received great attention with regard to their anticancer properties: 1) piperine, a dietary phytochemical isolated from black pepper (Piper nigrum L.) and long pepper (Piper longum L.); 2) sulforaphane, an isothiocyanate mainly derived from cruciferous vegetables; and 3) thymoquinone, the active compound from black seed (Nigella sativa L.). This review focused on the combined effect of these 3 compounds on conventional cancer therapy with the objective of observing enhanced efficacy compared with single treatments. This review also highlights the importance of the nanoformulation of such bioactive phytochemicals that could enhance their bioavailability by providing an efficient targeted delivery system with a reduced systemic dose while resulting in a more efficient dosing at the target site.
引用
收藏
页码:1600 / 1611
页数:12
相关论文
共 55 条
  • [1] Abdelhamed S, 2014, ANTICANCER RES, V34, P1893
  • [2] Antitumor effect of thymoquinone combined with resveratrol on mice transplanted with breast cancer
    Alobaedi, Omar H.
    Talib, Wamidh H.
    Basheti, Iman A.
    [J]. ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2017, 10 (04) : 378 - 386
  • [3] Anjum F., 2017, MOJ Drug Design Development Therapy, V1, P00006
  • [4] [Anonymous], 2017, BREAST CANC FACTS FI
  • [5] Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells
    Arafa, El-Shaimaa A.
    Zhu, Qianzheng
    Shah, Zubair I.
    Wani, Gulzar
    Barakat, Bassant M.
    Racoma, Ira
    El-Mandy, Mohamed A.
    Wani, Altar A.
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2011, 706 (1-2) : 28 - 35
  • [6] Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane
    Azarenko, Olga
    Okouneva, Tatiana
    Singletary, Keith W.
    Jordan, Mary Ann
    Wilson, Leslie
    [J]. CARCINOGENESIS, 2008, 29 (12) : 2360 - 2368
  • [7] Thymoquinone synergizes gemcitabine anti-breast cancer activity via modulating its apoptotic and autophagic activities
    Bashmail, Hanan A.
    Alamoudi, Aliaa A.
    Noorwali, Abdulwahab
    Hegazy, Gehan A.
    AJabnoor, Ghada
    Choudhry, Hani
    Al-Abd, Ahmed M.
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [8] Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model
    Bose, Chhanda
    Awasthi, Sanjay
    Sharma, Rajendra
    Benes, Helen
    Hauer-Jensen, Martin
    Boerma, Marjan
    Singh, Sharda P.
    [J]. PLOS ONE, 2018, 13 (03):
  • [9] Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells
    Burnett, Joseph P.
    Lim, Gi
    Li, Yanyan
    Shah, Ronak B.
    Lim, Rebekah
    Paholak, Hayley J.
    McDermott, Sean P.
    Sun, Lichao
    Tsume, Yasuhiro
    Bai, Shuhua
    Wicha, Max S.
    Sun, Duxin
    Zhang, Tao
    [J]. CANCER LETTERS, 2017, 394 : 52 - 64
  • [10] Chakraborty Chiranjib, 2018, Oncotarget, V9, P10164, DOI 10.18632/oncotarget.24309